Researchers found that in a model of disseminated lung cancer resistant to PD-1 immunotherapy, intratumoral virotherapy elicits CD8+ T-cell responses against a set of cancer-specific neoepitopes, overcoming systemic resistance to PD-1 immunotherapy (135). Here, CD8A is linked to lung carcinoma.